Eli Lilly To Purchase Cooley-Led CrossBridge In $300M Deal
CrossBridge Bio Inc., a venture-backed pre-clinical biotechnology firm advised by Cooley LLP, announced Tuesday that it has agreed to be bought by pharmaceutical giant Eli Lilly & Co. in a deal...To view the full article, register now.
Already a subscriber? Click here to view full article